Harvard T.H. Chan School of Public Health
Boston, Massachusetts, United States
Brendan Manning is Acting Chair and Professor in the Department of Molecular Metabolism at the Harvard T.H. Chan School of Public Health and faculty affiliate in the Department of Cell Biology at Harvard Medical School and of the Dana-Farber/Harvard Cancer Center. Dr. Manning received his BS from the University of Massachusetts, Amherst and his PhD from Yale University, then joined Harvard Medical School for his postdoctoral research. During this time, he discovered that the tuberous sclerosis complex (TSC) tumor suppressors serve as the molecular connection between the PI3K and mTOR pathways, thereby linking a signaling pathway activated in the majority of human cancers to a nutrient-sensing pathway that controls cell growth and metabolism. In 2004, he joined the faculty of the then newly established Department of Genetics and Complex Diseases at Harvard-Chan (renamed Molecular Metabolism in 2019) to continue research at the interface of signaling and metabolism. The Manning laboratory is primarily focused on understanding the functions of the PI3K-TSC-mTOR pathway in physiology and diseases with metabolic dysfunction at their core, including genetic tumor syndromes, cancer, diabetes, neurological disorders, and aging. Over the course of the past 20 years, Dr. Manning has served on the Scientific Advisory Board and Board of Directors of the Tuberous Sclerosis Complex Alliance, including as chair of its Science and Medical Committee. He is a two-time recipient of the National Cancer Institute’s Outstanding Investigator Award.
